Efficiency of Xenogeneic Antitumor Vaccine In Vivo

Didenko GV, Krutz OO, Konovalenko VF, Konovalenko SV, Bazas VN and Chekhun VF

RE Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, National Academy of Sciences, Ukraine

^*Correspondance to: Konovalenko SV 

 PDF  Full Text Research Article | Open Access

Abstract:

The antitumor efficiency of Xenogeneic Antitumor Vaccine (XAV) which is constructed with chicken embryonic proteins of higher molecular weight and cytotoxic metabolite of Bacillus subtilis B-7025 was shown at the experimental models of tumor growth (Lewis lung carcinoma and Ehrlich carcinoma). The use of XAV in animals with tumor process and in animals with surgical tumor removal significantly reduces the metastatic potential of tumors by maintaining the functional activity of lymphocytes and macrophages and by stimulating the transformation of plasminogen to angiostatin. At the later stages of tumor growth the antibody-dependent cytotoxicity of lymphocytes and macrophages increased in animals which were vaccinated.

Keywords:

Cancer vaccine; Circulating immune complexes; Cytotoxic activity; Tumor growth inhibition

Cite the Article:

Didenko GV, Krutz OO, Konovalenko VF, Konovalenko SV, Bazas VN, Chekhun VF. Efficiency of Xenogeneic Antitumor Vaccine In Vivo. Clin Oncol. 2020; 5: 1720.